Pilot-scale demonstration of an end-to-end integrated and continuous biomanufacturing process.

Autor: Coolbaugh MJ; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Varner CT; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Vetter TA; Global CMC Development, Sanofi, Framingham, Massachusetts, USA.; Gene Therapy Development, Pfizer, Chesterfield, Missouri, USA., Davenport EK; Global CMC Development, Sanofi, Framingham, Massachusetts, USA.; Process Science, Novartis Gene Therapies, San Diego, California, USA., Bouchard B; Global CMC Development, Sanofi, Framingham, Massachusetts, USA.; Process Development Systems, Moderna, Norton, Massachusetts, USA., Fiadeiro M; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Tugcu N; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Walther J; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Patil R; Global CMC Development, Sanofi, Framingham, Massachusetts, USA., Brower K; Global CMC Development, Sanofi, Framingham, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Biotechnology and bioengineering [Biotechnol Bioeng] 2021 Sep; Vol. 118 (9), pp. 3287-3301. Date of Electronic Publication: 2021 Jan 25.
DOI: 10.1002/bit.27670
Abstrakt: There has been increasing momentum recently in the biopharmaceutical industry to transition from traditional batch processes to next-generation integrated and continuous biomanufacturing. This transition from batch to continuous is expected to offer several advantages which, taken together, could significantly improve access to biologics drugs for patients. Despite this recent momentum, there has not been a commercial implementation of a continuous bioprocess reported in the literature. In this study, we describe a successful pilot-scale proof-of-concept demonstration of an end-to-end integrated and continuous bioprocess for the production of a monoclonal antibody (mAb). This process incorporated all of the key unit operations found in a typical mAb production process, including the final steps of virus removal filtration, ultrafiltration, diafiltration, and formulation. The end-to-end integrated process was operated for a total of 25 days and produced a total of 4.9 kg (200 g/day or 2 g/L BRX/day) of the drug substance from a 100-L perfusion bioreactor (BRX) with acceptable product quality and minimal operator intervention. This successful proof-of-concept demonstrates that end-to-end integrated continuous bioprocessing is achievable with current technologies and represents an important step toward the realization of a commercial integrated and continuous bioprocessing process.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: